Table S10.
Monotherapy network meta-analysis sensitivity analysis results for American College of Rheumatology (ACR) criteria scores of 20, 50, and 70 end point
| OR v PLA (95% CrI) | |||
|---|---|---|---|
|
|
|||
| ACR 20 | ACR 50 | ACR 70† | |
| Base case: random effects | |||
| ADA 40 mg/2 weeks | 5.125 (1.417, 18.62)‡ | 5.117 (1.819, 16.11)‡ | 11.71 (2.441, 77.5)‡ |
| ETN 2 25 mg/week | 12 (1.733, 90.94)‡ | 13.46 (2.631, 80.29)‡ | 20.83 (1.56, 1740)‡ |
| SUL | 1.608 (0.105, 27.48) | 2.379 (0.241, 25.64) | 1.14 (0.012, 178.8) |
| TOC 8 mg/kg/4 weeks | 26.25 (3.883, 190.8)‡ | 55.08 (6.204, 1740)‡ | 96.27 (3.992, 38820)‡ |
| As base case, but including TEMPO | |||
| ADA 40 mg/2 weeks | 5.076 (1.509, 17.53)‡ | 5.127 (1.902, 15.24)‡ | 11.38 (2.67, 74.92)‡ |
| ETN 2 25 mg/week | 8.209 (1.763, 38.24)‡ | 12.85 (3.355, 62.92)‡ | 21.17 (2.73, 316.1)‡ |
| SUL | 1.089 (0.101, 11.94) | 2.242 (0.292, 20.22) | 1.002 (0.018, 41.62) |
| TOC 8 mg/kg/4 weeks | 39.39 (7.95, 197.4)‡ | 48.87 (10.22, 310.7)‡ | 40.62 (4.862, 821.2)‡ |
Notes:
‡
Licensed treatments have significantly higher odds (based on the 95% CrI) compared to PLA;
†
for the ACR 70 network meta-analysis, a continuity correction (0.5) was applied to the data.
Abbreviations: ADA, adalimumab; CrI, credible interval (Bayesian probability interval); ETN, etanercept; exp, experienced; OR, odds ratio; PLA, placebo; SUL, sulfasalazine; TOC, tocilizumab.